AGTC News and Press, Applied Genetic Technologies Corporation From 03/21/22

Applied Genetic Technologies (NASDAQ:AGTC) said it has started a public offering of its common stock that will see underwriters' overallotment option to purchase up to an additional 15% of shares offered. Size, price and other terms of the offering not yet determined. The company intends to u...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treat...

Applied Genetic Technologies Corporation (AGTC) Q2 2022 Earnings Conference Call February 14, 2022 8:00 AM ET Company Participants Sue Washer – Chief Executive Officer Susan Schneider – Chief Medical Officer Jon Lieber – Chief Financial Officer Conference Call Participant...

Applied Genetic press release (NASDAQ:AGTC): Q2 GAAP EPS of -$0.45 misses by $0.06. As of December 31, 2021, the Company's cash and cash equivalents totaled $72.77M. For further details see: Applied Genetic GAAP EPS of -$0.45 misses by $0.06

-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq...

Applied Genetic Technologies (NASDAQ:AGTC) is scheduled to announce Q2 earnings results on Monday, Feb. 14, before market open. The consensus EPS estimate is -$0.39. Over the last 3 months, EPS estimates have seen 1 upward revision and 4 downward.  Last month, SA contributor Te...

AGTC, GTX, STNG, THS For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

AGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patients At the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on improvements in visua...

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment o...

Company on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 11, 20...